302 A phase IB study of indirect immunization with Oregovomab and TLR3 stimulation with hiltonol® (H) in patients with recurrent platinum resistant ovarian cancer (PROC)
302 A phase IB study of indirect immunization with Oregovomab and TLR3 stimulation with hiltonol® (H) in patients with recurrent platinum resistant ovarian cancer (PROC)